Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity.

Maynard S, Hay P, Chimoriya R, Acosta Reyes P, Grudzinskas K, Kormas N, Piya MK

The International journal of eating disorders26 Oct 2025Cited by 1 (Europe PMC)

PMID41139846DOI10.1002/eat.24575PepBankPUB-41139846

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with class 3 obesity, people already taking GLP1-RA (a class, not only semaglutide) did not differ significantly in EDE-QS, K10 or DASS-21 scores from those not taking GLP1-RA.
In plain wordsIn adults with severe obesity, people already on GLP-1 drugs had similar eating disorder and distress scores to those not on them.
Peptide
Semaglutide
Outcome
No significant changeBaseline eating disorder risk and distress scores, on GLP1-RA versus not
Study
n = 666
Comparator
Not on GLP1-RA
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
Among 666 participants, 59 (9%) were on GLP1-RA at baseline, with no significant differences in EDE-QS, K10, or DASS-21 scores compared to those not on GLP1-RA.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational cohort study included adults with Class 3 obesity enrolled in a publicly funded multidisciplinary weight management program in Sydney from January 2018 to June 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4113984601
02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with class 3 obesity who started a GLP1-RA (mostly semaglutide 1 mg), median weight fell significantly over 12 months.
In plain wordsIn adults with severe obesity who started a GLP-1 drug, weight fell over 12 months.
Peptide
Semaglutide
Outcome
DecreaseWeight change after starting GLP1-RA
Study
n = 31
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Those initiated on GLP1-RA had a significant reduction in median weight, from 131.0 (118.7-149.6) kg at baseline to 120.0 (109.2-135.3) kg at 12 months, p < 0.001.
2 context sentences(design, population, supporting numbers)
Summary · context
Of 203 participants not on a GLP1-RA at baseline and having 12-month data, 31 (15.3%) initiated GLP1-RA treatment, with the majority on semaglutide 1 mg and a mean duration of use of 7.1 ± 3.7 months.
Summary · context
This retrospective observational cohort study included adults with Class 3 obesity enrolled in a publicly funded multidisciplinary weight management program in Sydney from January 2018 to June 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4113984602
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with class 3 obesity who started a GLP1-RA, eating disorder risk (EDE-QS) did not change significantly over 12 months.
In plain wordsIn adults with severe obesity who started a GLP-1 drug, eating disorder risk scores did not change significantly over 12 months.
Peptide
Semaglutide
Outcome
No significant changeEDE-QS change from baseline to 12 months
Study
n = 31
Comparator
Baseline
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
There were no statistically significant changes in EDE-QS, K10, and DASS-21 scores from baseline to 12 months, and none stopped GLP1-RA due to ED symptoms or psychological distress.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational cohort study included adults with Class 3 obesity enrolled in a publicly funded multidisciplinary weight management program in Sydney from January 2018 to June 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4113984603
04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with class 3 obesity who started a GLP1-RA, psychological distress (K10) did not change significantly over 12 months.
In plain wordsIn adults with severe obesity who started a GLP-1 drug, distress scores did not change significantly over 12 months.
Peptide
Semaglutide
Outcome
No significant changeK10 change from baseline to 12 months
Study
n = 31
Comparator
Baseline
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
There were no statistically significant changes in EDE-QS, K10, and DASS-21 scores from baseline to 12 months, and none stopped GLP1-RA due to ED symptoms or psychological distress.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational cohort study included adults with Class 3 obesity enrolled in a publicly funded multidisciplinary weight management program in Sydney from January 2018 to June 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4113984604
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with class 3 obesity who started a GLP1-RA, depression, anxiety and stress scores (DASS-21) did not change significantly over 12 months.
In plain wordsIn adults with severe obesity who started a GLP-1 drug, depression, anxiety and stress scores did not change significantly over 12 months.
Peptide
Semaglutide
Outcome
No significant changeDASS-21 change from baseline to 12 months
Study
n = 31
Comparator
Baseline
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
There were no statistically significant changes in EDE-QS, K10, and DASS-21 scores from baseline to 12 months, and none stopped GLP1-RA due to ED symptoms or psychological distress.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational cohort study included adults with Class 3 obesity enrolled in a publicly funded multidisciplinary weight management program in Sydney from January 2018 to June 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4113984605
06HumanNot a test of Semaglutide aloneObservational studySafety outcome
In adults with class 3 obesity who started a GLP1-RA, none stopped treatment because of eating disorder symptoms or psychological distress.
In plain wordsIn adults with severe obesity who started a GLP-1 drug, no one stopped it because of eating disorder symptoms or distress.
Peptide
Semaglutide
Outcome
No significant changeDiscontinuation due to eating disorder symptoms or distress
Study
n = 31
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
and none stopped GLP1-RA due to ED symptoms or psychological distress.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational cohort study included adults with Class 3 obesity enrolled in a publicly funded multidisciplinary weight management program in Sydney from January 2018 to June 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4113984606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.